Compare MFA & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MFA | LBRX |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | N/A | 27 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 850.5M |
| IPO Year | N/A | N/A |
| Metric | MFA | LBRX |
|---|---|---|
| Price | $9.42 | $27.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $11.05 | ★ $46.60 |
| AVG Volume (30 Days) | ★ 1.4M | 140.2K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 14.16% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.02 | N/A |
| P/E Ratio | $7.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.78 | $13.40 |
| 52 Week High | $10.57 | $33.47 |
| Indicator | MFA | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.44 | 40.86 |
| Support Level | $9.38 | $22.39 |
| Resistance Level | $10.26 | $33.47 |
| Average True Range (ATR) | 0.22 | 1.68 |
| MACD | -0.08 | -0.60 |
| Stochastic Oscillator | 9.55 | 11.96 |
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.